AccuMetab™ Human CYP2A6 Enzyme, Catalytically Active

CAT#: ITS-0426-YL17
Product Type: Recombinant Phase I Metabolizing Enzyme
Brand: AccuMetab
Development Stage: ADME
ADME Research Domain: Metabolism
Short Description
Human CYP2A6 for accurate Phase I drug metabolism profiling.
Brand
AccuMetab
Development Stage
ADME
ADME Research Domain
Metabolism
Background
CYP2A6 is the principal enzyme driving the hepatic clearance of nicotine and the metabolic activation of several procarcinogens. It is heavily utilized in ADME studies focusing on smoking cessation therapies, prodrug activation mechanisms, and specific hepatocarcinogenic risk assessments.
Key Features
Proprietary E. coli expression; Pre-coupled with native human reductase; Validated for nicotine and coumarin metabolism; Essential for smoking cessation therapeutic screening
Applications
Drug Metabolism Studies, Reaction Phenotyping, DDI Assessment, Metabolite ID
Research Areas
ADME; Toxicology; Drug-Drug Interactions (DDI)
Species
Human
Expression System
Recombinant enzymes prepared from E. coli and co-expressed with NADPH CYP-reductase.
Physical Form
Liquid
Size
0.5 nmol; 1 nmol; 4 nmol; 10 mg
Storage
-80°C
Storage Comment
When stored at -80°C, our product remains stable and retains full functional activity for up to 10 years.
Note
For bulk pricing or custom reagent inquiries, please contact us by email or phone. Products are shipped on ice via FedEx.
Restrictions
For Research Use Only (RUO). Not intended for diagnostic or therapeutic use.
Shipping
Our enzyme products are shipped at -80°C.
For Research Use Only | Not For Clinical Use
Online Inquiry